Invivyd, Inc. - Common Stock IVVD 深 滬
已收盤 08-15 16:00:00 美东时间
0.7071
-0.092
-11.54%
華盛通- 最 高0.7671
- 今 開0.717
- 成交量 142.38万股
- 最 低 0.68
- 昨 收 0.7993
- 總市值 8485.20万
- 52周最高 2.74
- 市盈率 靜 --
- 換手率 1.19%
- 52周最低 0.3546
- 委 比 7.96%
- 總股本 1.20亿
- 歷史最高 78.82
- 量 比 2.91
- 振 幅 10.90%
- 歷史最低 0.3546
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Invivyd Q2 EPS $(0.12) Misses $(0.01) Estimate, Sales $11.79M Miss $23.16M Estimate
Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.01) by 1614.29 percent. This is a 70 percent increase over losses of $(0.40) per share from the same
08-15 04:51
Invivyd Secures FDA Alignment On Accelerated BLA Pathway For VYD2311 With Single Phase 2/3 Trial Targeting Symptomatic COVID-19 Reduction As Primary Endpoint
Alignment follows Type C meeting for VYD2311 as previously disclosedBLA pathway for VYD2311 to be supported by a single, Phase 2/3 randomized, double-blind, placebo-controlled trial with a primary endpoint of reduction
08-15 04:48
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
Invivyd, Inc. announced alignment with FDA advice for a rapid pathway to BLA approval for VYD2311, a monoclonal antibody for COVID-19 prevention. The company plans a Phase 2/3 trial with a primary endpoint of reducing symptomatic COVID-19, targeting broad populations including adults, adolescents, and potentially children. VYD2311 aims to be a low-dose, scalable, long-lasting alternative to vaccines, with a 12-week primary endpoint analysis for r...
08-14 20:47
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
Invivyd, Inc. has announced the addition of Dr. Akiko Iwasaki to the SPEAR Study Group, focusing on the biology and clinical effects of the persistent SARS-CoV-2 spike antigen. Her expertise in viral pathogenesis and post-viral chronic conditions, including Long COVID and PVS, will guide the group's efforts to explore the safety and efficacy of monoclonal antibodies in treating these conditions. The SPEAR Study Group is planning clinical trials u...
07-23 11:01
Invivyd Says Updated NCCN Guidelines For Prevention And Treatment Of Cancer-Related Infections Now Recommend Use Of Available Monoclonal Antibodies For Pre-Exposure Prophylaxis Of COVID-19
NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer
07-21 19:11
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
The updated NCCN guidelines now recommend monoclonal antibodies for COVID-19 prevention in cancer patients. This aligns with IDSA and CDC guidance, emphasizing their role in protecting immunocompromised individuals. New research highlights the significant impact of COVID-19 on cancer patients, including treatment delays and severe complications. Monoclonal antibodies offer targeted protection, reducing risks and ensuring continuity of care. These...
07-21 11:05
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
Invivyd, Inc. has formed the SPEAR Study Group to evaluate the potential of monoclonal antibody therapy, including PEMGARDA (pemivibart), for treating Long COVID and Post-Vaccination Syndrome (PVS). The group, led by experts in Long COVID biology, aims to conduct rigorous clinical trials assessing the safety, efficacy, and translational biology of anti-SARS-CoV-2 spike protein antibodies in patients with persistent viral exposure. This initiative...
07-02 11:01
美股大行评级 | 潜在涨幅205.56%！康托·菲茨杰拉德上调HIVE Digital Technologies目标价至5.5美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1145638202455883776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 康托·菲茨杰拉德：维持HIVE Digital Technologies(HIVE)"超配"评级，目标价从5美元升至5.5美元</p> <p>• BTIG：维持Theravance Biopharma(TBPH)"买入"评
06-28 08:37
美股大行评级 | 潜在涨幅61.27%！Loop Capital上调英伟达目标价至250美元，维持"买入"评级
今日重点评级关注：Benchmark：维持特斯拉(TSLA)"买入"评级，目标价从350美元升至475美元>>
06-27 08:37
D. Boral Capital Maintains Buy on Invivyd, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains Invivyd (NASDAQ:IVVD) with a Buy and maintains $9 price target.
06-26 20:15
